Literature DB >> 29621846

The CRISP-Q study: Communicating the risks and benefits of colorectal cancer screening

Grace Y Kim1, Jennifer G Walker2, Adrian Bickerstaffe3, Nadira Hewabandu4, Marie Pirotta5, Louisa Flander6, Mark Jenkins7, Jon D Emery8.   

Abstract

Background and objectives: Many Australians at average risk of colorectal cancer (CRC) are undergoing unnecessary colonoscopic screening, while many at increased risk are getting inadequate screening. The aim of this study was to test different ways of communicating the risks and benefits of CRC screening, as part of the development of a CRC risk prediction (CRISP) tool. Method: General practice patients were shown five different risk presentations for hypothetical ‘average’ and ‘increased’ risk cases and were asked to choose the screening method they would undergo. Associations were explored between risk presentation type and ‘risk-appropriate screening’ choice.
Results: All risk formats were associated with improved risk-appropriate screening by participants (n = 204); however, there was a statistical trend favouring absolute risk with a government recommendation and an ‘expected frequency tree’. The icon array was most weakly associated with appropriate screening. Discussion: This research will inform approaches to communicating risk in CRISP and may be of wider relevance to supporting informed decisions about cancer screening.

Entities:  

Mesh:

Year:  2018        PMID: 29621846     DOI: 10.31128/AFP-04-17-4195

Source DB:  PubMed          Journal:  Aust J Gen Pract


  6 in total

1.  Benefits and harms of aspirin to reduce colorectal cancer risk: a cross-sectional study of methods to communicate risk in primary care.

Authors:  Peter Nguyen; Jennifer McIntosh; Adrian Bickerstaffe; Sanjaya Maddumarachchi; Kara-Lynne Cummings; Jon D Emery
Journal:  Br J Gen Pract       Date:  2019-11-28       Impact factor: 5.386

2.  Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.

Authors:  Jennifer G McIntosh; Jesse Minshall; Sibel Saya; Adrian Bickerstaffe; Nadira Hewabandu; Ashleigh Qama; Jon D Emery
Journal:  Br J Gen Pract       Date:  2019-11-28       Impact factor: 5.386

3.  Commentary: Pivoting during a pandemic: developing a new recruitment model for a randomised controlled trial in response to COVID-19.

Authors:  Shakira Milton; Jennifer McIntosh; Lucy Boyd; Napin Karnchanachari; Finlay Macrae; Jon David Emery
Journal:  Trials       Date:  2021-09-08       Impact factor: 2.279

4.  The SCRIPT trial: study protocol for a randomised controlled trial of a polygenic risk score to tailor colorectal cancer screening in primary care.

Authors:  Sibel Saya; Lucy Boyd; Patty Chondros; Mairead McNamara; Michelle King; Shakira Milton; Richard De Abreu Lourenco; Malcolm Clark; George Fishman; Julie Marker; Cheri Ostroff; Richard Allman; Fiona M Walter; Daniel Buchanan; Ingrid Winship; Jennifer McIntosh; Finlay Macrae; Mark Jenkins; Jon Emery
Journal:  Trials       Date:  2022-09-27       Impact factor: 2.728

5.  The use of a risk assessment and decision support tool (CRISP) compared with usual care in general practice to increase risk-stratified colorectal cancer screening: study protocol for a randomised controlled trial.

Authors:  Jennifer G Walker; Finlay Macrae; Ingrid Winship; Jasmeen Oberoi; Sibel Saya; Shakira Milton; Adrian Bickerstaffe; James G Dowty; Richard De Abreu Lourenço; Malcolm Clark; Louise Galloway; George Fishman; Fiona M Walter; Louisa Flander; Patty Chondros; Driss Ait Ouakrim; Marie Pirotta; Lyndal Trevena; Mark A Jenkins; Jon D Emery
Journal:  Trials       Date:  2018-07-25       Impact factor: 2.279

6.  The impact of hypothetical PErsonalised Risk Information on informed choice and intention to undergo Colorectal Cancer screening colonoscopy in Scotland (PERICCS)-a randomised controlled trial.

Authors:  Jayne Digby; Ronan E O'Carroll; Julie A Chambers; Robert J C Steele
Journal:  BMC Med       Date:  2020-10-20       Impact factor: 8.775

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.